Thus, it warrants clinical consideration that limitations exist in evaluating CHD risk using HDL-c or ALB alone, given their susceptibility to confounding factors such as inflammation, nutrition, and comorbidities. The gene discussed is ALB; the disease is coronary artery disorder.